July 07, 2020
1 min read
Save

FDA accepts premarket approval application for DE-128

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA has accepted the premarket approval application for Santen Pharmaceutical’s DE-128 microshunt for review, according to a press release.

The ab-externo MIGS device is intended for reduction of IOP in patients with primary open-angle glaucoma whose disease is not well controlled using maximum tolerated glaucoma medications.

In a previously reported multicenter study, the microshunt reduced mean diurnal IOP reduction from 21.1 mm Hg to 14.2 mm Hg at month 12 compared with a reduction from 21.1 mm Hg to 11.2 mm Hg in a standard of care trabeculectomy group. Number of medications were reduced in both groups, and no patients in the DE-128 arm required suture lysis. The rate of hypotony in the microshunt arm was less than in the trabeculectomy arm.

An FDA decision is expected in about 6 months.